Siyomicro Secures Hundred-Million-Yuan Financing: Further Consolidate AI+BT Synthetic Biology Platform and Expand into Bulk Biomanufacturing Products

As learned by Arterial Network, Shenzhen Siyomicro BIO-TECH Co., Ltd. announced today the completion of its hundred-million-yuan financing round. The financing was led by a well-known industrial investor, with Goldport Capital and Shenzhen Longgang District Guidance Fund participating as follow-on investors. The raised funds will be mainly used for the construction of its synthetic biology platform, further accelerating the development of multiple chassis cells and product industrialization, as well as advancing the strategic layout of bulk biomanufactured products. CEC CAPITAL served as the exclusive financial advisor to Siyomicro for this transaction.

Biomanufacturing, a core future industry for developing new quality productive forces, has been elevated to a national strategic level. According to the Outline of the 15th Five-Year Plan, China targets to expand the total scale of its biomanufacturing industry to over 5 trillion yuan by 2030. This represents nearly 350% growth compared with the 1.1 trillion yuan recorded at the end of 2025. Continued policy dividends will unlock broad growth prospects for the sector. Meanwhile, the 15th Five-Year Plan explicitly supports the development of non-food bio-based technologies to address the longstanding pain point of "competing with humans for food and with livestock for feed" under prevailing biomanufacturing models. Biomanufacturing relying on non-food raw materials has become an inevitable path for sustainable industrial development.

Centered on the integrated innovation of AI+BT, the company has built three major R&D platforms: the synthetic biology intelligent computing platform, biochip platform and high-throughput automation platform, establishing industry-leading technical barriers and rapid R&D iteration capabilities. Its self-developed extremophilic microbial resource database has accumulated 8 million unique extrem enzyme elements, 93% of whose sequences are unavailable in international public databases. The database supports rational strain design and enzyme protein engineering, forming a complete innovation chain covering biological resource mining, element development and industrial implementation, and consolidating independent underlying technological capabilities.

Siyomicro has entered the fast track of commercialization across multiple fields. It has built multi-layer business curves and achieved leapfrog growth in performance.

Having completed market validation of high-value-added raw materials, the company further expands into organic acid materials, animal feed and other sectors to pursue the larger track of bulk bio-based products.

Siyomicro has successfully developed a proprietary filamentous fungi chassis, covering high-efficiency recombinant protein secretion systems, potent gene-editing tools, high-throughput strain screening and controllable fermentation processes, building solid technological moats. Going forward, Siyomicro will expand from high-value fine raw materials into the bulk biological products market. Leveraging its filamentous fungi chassis, the company will advance pipelines including organic acids, animal feed and bio-based materials, broaden the application boundary of synthetic biology technologies, drive the large-scale, low-carbon and independent development of China’s biomanufacturing sector, and unlock the long-term potential of the biomanufacturing industry.